arctigenin has been researched along with cyclin d1 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Liu, C; Luo, L; Yao, X; Yin, Z; Zhao, Z; Zhu, F | 1 |
Feng, S; Li, X; Liu, Y; Lv, X; Ma, J; Xiao, J; Yang, H; Yang, S; Zhang, Y | 1 |
Li, A; Wang, J; Wu, M; Zhang, H; Zhang, X | 1 |
Liu, XP; Shao, TL; Shen, XB; Wang, GD; Yuan, PC; Zhu, L | 1 |
Lee, KS; Lee, MG; Nam, KS | 1 |
5 other study(ies) available for arctigenin and cyclin d1
Article | Year |
---|---|
Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Blotting, Western; Cell Line, Tumor; Cisplatin; Cyclin D1; Flow Cytometry; Furans; G1 Phase; HeLa Cells; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 1; Janus Kinase 2; Lignans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Signal Transduction; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2011 |
Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Flow Cytometry; Furans; Humans; Lignans; Mitogen-Activated Protein Kinases; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2012 |
The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Becaplermin; Cell Line; Cell Nucleus; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Furans; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Hepatic Stellate Cells; Humans; Lignans; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Resting Phase, Cell Cycle; RNA, Small Interfering; Signal Transduction | 2015 |
Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Female; Furans; Glycogen Synthase Kinase 3; Humans; Lignans; MCF-7 Cells; Proteolysis; Receptors, Estrogen | 2020 |
Combined doxorubicin and arctigenin treatment induce cell cycle arrest-associated cell death by promoting doxorubicin uptake in doxorubicin-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Doxorubicin; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Necrosis | 2023 |